Public policy assumptions, which view "the public" as passive consumers, are deeply flawed. "The public" are, in fact, active citizens, who constitute the innovation end of the seamless web of relationships, running from research and development laboratory to shop, hospital or farm, or local neighborhood. "The public" do not receive the impact of technology; they are the impact, in that they determine with gene technology (GT) developers and sellers what happens to the technology in our society. In doing so, they, or more rightly we, exercise particular, contextual knowledges and actions. We suggest that it is the ignorance of this aspect of innovation in policy processes that produces the distrust and resentment that we found in our interviews with "publics" interested in gene technology. This is consistent with Beck's description of the deep structural states of risk and fear in modern advanced societies with respect to new technologies, such as gene technology. Only policy processes that recognize the particular, local and contextual knowledges of "the public", which co-construct innovation, can achieve deep, social structural consideration of gene technology. And only such a deep consideration can avoid the polarized attitudes and deep suspicions that we have seen arise in places such as Britain. Such consideration needs the type of processes that involve active consultation and inclusion of "the public" in government and commercial innovation, the so-called deliberative and inclusionary processes (DIPs), such as consensus conferences and citizen juries. We suggest some measures that could be tried in Australia, which would take us further down the path of participation toward technological citizenship.

The authors analyze the framework for public participation in Australian biotechnology policy and argue that participation is undermined by the institutional structures that were ostensibly designed to facilitate consultation. They conclude that for the moment, community consultation in the formulation of Australian biotechnology policy appears limited. Indeed, the Australian Gene Technology Act 2000 and the Gene Technology Community Consultative Committee Operating Procedures effectively exclude the community from participating in deliberations on biotechnology policy. The community continues to be treated as consumers of advice, rather than technological citizens who can make a genuine contribution to biotechnology policy.